Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Gyre Therapeutics Inc

GYRE ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Small Cap Analyst: BUY

Last Close

$6.68

▲ +2.14%

Market Cap $708.31M · Vol 15.91K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$708.31M

Small Cap

Div Yield

N/A

Dividend with no set frequency

EPS Growth

-350.00%

YoY

RSI (14)

63.41

Momentum

Beta

1.77

vs Market

52W High

$9.42

29.09% below

52W Low

$5.45

22.57% above

Volume

15.91K

Avg 25.70K

P/B

6.08

Price-to-book

ROE

N/A

Return on equity

Free Float

25.60%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Gyre Therapeutics Inc (GYRE) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does GYRE pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+0.15%

+5.36%

-4.57%

-16.71%

YTD

-5.38%

-18.73%

+20.36%

-33.26%

Financials & Valuation

TTM · Annual

Total Revenue	$116.59M
Net Income	$9.88M
Revenue Growth (YoY)	+8.72%
Gross Margin	95.35%
Operating Margin	9.86%
Net Profit Margin	8.47%
ROE	N/A
ROA · ROIC	9.90% · 4.18%

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	-5.90
P/S	6.25
P/B	6.08
P/FCF	N/A
EPS Growth	-350.00%
Outstanding Shares	106.03M

Technical Indicators

50-Day SMA	$6.30
200-Day SMA	$7.22
RSI (14)	63.41
Beta	1.77
52-Week High	$9.42
52-Week Low	$5.45

Volume Today	15.91K
Avg Daily Volume (30D)	25.70K
Relative Volume	0.62x
Volatility (10D)	35.60
Volatility (30D)	46.45
Free Float	25.60%

Analyst Consensus

BUY

Current Price $6.68

Mean Target $18.67

52W Low$5.45 52W High$9.42

Current

Target

$5.45 $9.42

Current Analyst target

+179.44% upside potential · 3 analysts

Identifiers

ExchangeNasdaq

FIGIBBG001SDL5X7

ISINUS4037831033

CountryUnited States of America

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateOct 30, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG -1.78% RVMD Revolution Medicines Inc +0.85% ONC BeOne Medicines AG -2.40% 068270.KS Celltrion Inc -0.50% ABVX Abivax SA -2.05%

Company Profile

Gyre Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of F351 (Hydronidone) for the treatment of MASH-associated fibrosis in the United States. It is also advancing a diverse pipeline in the PRC through its controlling interest in Gyre Pharmaceuticals, including therapeutic expansions of ETUARY, and development programs for F573, and F528. F351 is a structural derivative of ETUARY. F573 is its clinical-stage product candidate for the treatment of acute/acute-on-chronic liver failure (ALF/ACLF) in Phase 2 clinical trials in the PRC. F528 is a preclinical-stage candidate targeting chronic obstructive pulmonary disease. It is focused on commercializing therapies for the treatment of pulmonary fibrosis through its two therapeutic products: ETUARY (pirfenidone) and nintedanib. It is also focused on commercializing the avatrombopag product and discovery and development of targeted protein degrader and degrader antibody conjugate therapies.